Dr. Bauml Discusses the FLAURA Study in NSCLC

Name: Dr. Bauml Discusses the FLAURA Study in NSCLC
Uploaded: 2017-09-19T00:35:00.000Z
Description: Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses the FLAURA trial in patients with EGFR-mutant non–small cell lung cancer.

September 18, 2017

Joshua Bauml, MD

Video

Conference|ESMO Congress

Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses the FLAURA trial in patients with EGFR-mutant non–small cell lung cancer.

Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses the FLAURA trial in patients with EGFR-mutant non—small cell lung cancer (NSCLC).

FLAURA is a randomized phase III study of frontline osimertinib (Tagrisso) compared with either erlotinib (Tarceva) or gefitinib (Iressa).

Results showed an improvement in progression-free survival, and a trend was observed toward overall survival with osimertinib—though it is not yet statistically significant.